» Articles » PMID: 38127898

Evaluation of Anticancer Potential of Tetracene-5,12-dione (A01) and Pyrimidine-2,4-dione (A02) Via Caspase 3 and Lactate Dehydrogenase Cytotoxicity Investigations

Overview
Journal PLoS One
Date 2023 Dec 21
PMID 38127898
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer stands as a significant global cause of mortality, predominantly arising from the dysregulation of key enzymes and DNA. One strategic avenue in developing new anticancer agents involves targeting specific proteins within the cancer pathway. Amidst ongoing efforts to enhance the efficacy of anticancer drugs, a range of crucial medications currently interact with DNA at the molecular level, exerting profound biological effects. Our study is driven by the objective to comprehensively explore the potential of two compounds: (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione (A01) and 5-fluoro-1H-pyrimidine-2,4-dione (A02). These compounds have demonstrated marked efficacy against breast and cervical cancer cell lines, positioning them as promising anticancer candidates. In our investigation, A01 has emerged as a particularly potent candidate, with its potential bolstered by corroborative evidence from lactate dehydrogenase release and caspase-3 activity assays. On the other hand, A02 has exhibited remarkable anticancer potential. To further elucidate their molecular mechanisms and interactions, we employed computational techniques, including molecular docking and molecular dynamics simulations. Notably, our computational analyses suggest that the A01-DNA complex predominantly interacts via the minor groove, imparting significant insights into its mechanism of action. While earlier studies have also highlighted the anticancer activity of A01, our research contributes by providing a deeper understanding of its binding mechanisms through computational investigations. This knowledge holds potential for designing more effective drugs that target cancer-associated proteins. These findings lay a robust groundwork for future inquiries and propose that derivatives of A01 could be synthesized as potent bioactive agents for cancer treatment. By elucidating the distinctive aspects of our study's outcomes, we address the concern of distinguishing our findings from those of prior research.

Citing Articles

Efficient analysis of adverse drug events and toxicological mechanisms of newly marketed drugs by integrating pharmacovigilance and network toxicology: selumetinib as an example.

Xiong R, Lei J, Wang L, Zhang S, Liu H, Wang H Front Pharmacol. 2024; 15:1432759.

PMID: 39193326 PMC: 11347787. DOI: 10.3389/fphar.2024.1432759.

References
1.
Qi F, Li A, Inagaki Y, Gao J, Li J, Kokudo N . Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trends. 2011; 4(6):297-307. View

2.
Yoshida K, Miki Y . The cell death machinery governed by the p53 tumor suppressor in response to DNA damage. Cancer Sci. 2010; 101(4):831-5. PMC: 11158978. DOI: 10.1111/j.1349-7006.2010.01488.x. View

3.
Chen W, Li Z, Bai L, Lin Y . NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front Biosci (Landmark Ed). 2011; 16(3):1172-85. PMC: 3032584. DOI: 10.2741/3782. View

4.
Trott O, Olson A . AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2009; 31(2):455-61. PMC: 3041641. DOI: 10.1002/jcc.21334. View

5.
Wani T, Zargar S, Alkahtani H, Altwaijry N, Al-Rasheed L . Anticancer Potential of Sulfonamide Moieties via In-Vitro and In-Silico Approaches: Comparative Investigations for Future Drug Development. Int J Mol Sci. 2023; 24(9). PMC: 10178775. DOI: 10.3390/ijms24097953. View